TL;DR: The U.S. Department of Justice has opened formal hearings in late June 2026 to evaluate rescheduling adult-use cannabis from Schedule I, following the landmark April 23 move of medical cannabis to Schedule III. A successful outcome would eliminate 280E taxation entirely for multi-state operators (MSOs), potentially unlocking hundreds of millions in annual cash flow across the sector. Major MSO equities have surged an average of 38% in Q2 as investors price in the probability of full relief.
Market Analysis
The April 23 partial rescheduling — which reclassified medical cannabis from Schedule I to Schedule III — served as the starting gun for a significant Q2 MSO rally. The AdvisorShares Pure US Cannabis ETF (MSOS) has gained 48.5% since the end of Q1 2026 and is now up 11.7% year-to-date. Six MSOs tracked in the New Cannabis Ventures Global Cannabis Stock Index averaged 38.1% returns in Q2 alone, with two names posting particularly outsized gains.
Key beneficiaries of rescheduling sentiment include Curaleaf Holdings (OTC: CURLF) and Green Thumb Industries (OTC: GTBIF), both of which carry significant multi-state retail and cultivation footprints that are directly exposed to 280E tax treatment. Cresco Labs (OTC: CRLBF) and Trulieve Cannabis (OTC: TCNNF) also stand to benefit materially, given their scale and the magnitude of their deferred 280E liabilities. The Global Cannabis Stock Index, which had been down 12.6% year-to-date through late May, has recovered substantially on the regulatory tailwind.
It is important to note, however, that 14 of the 23 names in the index have returned less than the index itself — a reminder that individual stock selection remains critical even in a rising regulatory tide. Track current cannabis equity performance at the cannabis stock tracker.
Context & Regulatory Backdrop
The April 23 rescheduling action was historic: the first time the U.S. federal government reclassified cannabis under the Controlled Substances Act. Medical cannabis is now Schedule III, which eliminates Internal Revenue Code Section 280E tax treatment for the medical-use portion of cannabis company revenues. This alone is significant — but the hearings now underway represent the next, potentially more impactful phase.
If adult-use cannabis is similarly rescheduled, 280E taxation ends entirely. Cannabis companies currently cannot deduct standard business expenses — cost of goods sold is the only allowable deduction — resulting in effective tax rates that can exceed 70% of pre-tax income for profitable MSOs. Eliminating 280E would represent a transformational improvement in after-tax cash flow across the industry.
Several material uncertainties remain. First, the disposition of historical unpaid 280E tax liabilities, which many cannabis companies carry as contingent liabilities rather than debt on their balance sheets, is unresolved. Second, SAFER Banking Act progress — which would allow cannabis companies to access normal commercial banking services — remains stalled in the Senate. Third, exchange uplisting (NYSE/Nasdaq eligibility for MSOs) is still not on a defined legislative or regulatory path. Each of these issues represents both a risk and a potential catalyst depending on resolution timing.
Forward-Looking View
The DOJ hearings represent a genuine inflection point for the cannabis sector. Market participants should monitor hearing progress closely — procedurally, the DOJ has 90 days to issue findings, though timelines can extend. For institutional investors maintaining or building cannabis exposure, the hearing outcomes will be the primary determinant of near-term sector direction.
In a full-rescheduling scenario, the fundamental earnings power of the largest MSOs improves dramatically, and exchange uplisting becomes a realistic near-term possibility — which would open cannabis equities to a far broader institutional investor base. In a partial or stalled scenario, the April rally thesis weakens and the sector reverts to fundamentals-driven trading, where balance sheet strength and free cash flow generation separate winners from losers. CURLF, GTBIF, and the MSOS ETF remain the most liquid proxies for directional cannabis sector exposure through this regulatory transition.